ProfileOfResearchers

TÃTULO: Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Race and endometrial carcinoma recurrence Full Text
AUTORES: Felix A.S.; Brasky T.M.; Cohn D.E.; Mutch D.G.; Creasman W.T.; Thaker P.H.; Walker J.L.; Moore R.G.; Lele S.B.; Guntupalli S.R.; Downs L.S.; Ci Nagel; Boggess J.F.; Pearl M.L.; Ioffe O.B.; Deng W.; David Scott Miller ; Brinton L.A.;
PUBLICAÇÃO: 2018, FONTE: International Journal of Cancer, VOLUME: 142, NÚMERO: 6

INDEXADO EM:

Scopus

NO MEU:

ORCID |

TÃTULO: Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer
AUTORES: Lavanya H Palavalli Parsons; Brandon Roane; Dustin B Manders; Debra L Richardson; Siobhan M Kehoe; Matthew Carlson; David Scott Miller ; Jayanthi S Lea;
PUBLICAÇÃO: 2018, FONTE: American Journal of Clinical Oncology: Cancer Clinical Trials, VOLUME: 41, NÚMERO: 10

INDEXADO EM:

Scopus

NO MEU:

ORCID |

TÃTULO: Locally Advanced Cervical Cancer: Outcomes with Variable Adherence to Treatment. Outcomes With Variable Adherence to Treatment
AUTORES: Dustin B Manders; Abel Morón; Donald McIntire; David Scott Miller ; Debra L Richardson; Siobhan M Kehoe; Kevin V Albuquerque; Jayanthi S Lea;
PUBLICAÇÃO: 2018, FONTE: American Journal of Clinical Oncology: Cancer Clinical Trials, VOLUME: 41, NÚMERO: 5

INDEXADO EM:

Scopus

NO MEU:

ORCID |

TÃTULO: Pre-operative core muscle index in combination with hypoalbuminemia is associated with poor prognosis in advanced ovarian cancer Full Text
AUTORES: Lesley B Conrad; Haitham Awdeh; Stefany Acosta Torres; Steven A Conrad; April A Bailey; David Scott Miller ; Jayanthi S Lea;
PUBLICAÇÃO: 2018, FONTE: Journal of Surgical Oncology, VOLUME: 117, NÚMERO: 5

INDEXADO EM:

Scopus

NO MEU:

ORCID |

TÃTULO: Prognostic Significance of Nodal Location and Ratio in Stage IIIC Endometrial Carcinoma among a Multi-Institutional Academic Collaboration
AUTORES: Jyoti Mayadev; Mohamed A Elshaikh; Alana Christie; Christa Nagel; Vanessa Kennedy; Nadia Khan; Jayanthi Lea; Ahmad Ghanem; David Scott Miller ; Xian Jin Xie; Michael Folkert; Kevin Albuquerque;
PUBLICAÇÃO: 2018, FONTE: American Journal of Clinical Oncology: Cancer Clinical Trials, VOLUME: 41, NÚMERO: 12

INDEXADO EM:

Scopus

NO MEU:

ORCID |

TÃTULO: QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.
AUTORES: Kathleen N Moore; Angeles Alvarez Secord; Melissa Ann Geller; David Scott Miller ; Noelle Gillette Cloven; Gini F Fleming; Andrea Elisabeth Wahner Hendrickson; Masoud Azodi; Paul DiSilvestro; Amit M Oza; Mihaela C Cristea; Jonathan S Berek; John K Chan; Yong Li; Romnee Clark; Ursula A Matulonis; Bradley J Monk;
PUBLICAÇÃO: 2018, FONTE: Journal of Clinical Oncology, VOLUME: 36, NÚMERO: 15_suppl

INDEXADO EM:

CrossRef: 19

NO MEU:

ORCID |

TÃTULO: QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset
AUTORES: K.N Moore; A.A Secord; Geller, M; David Scott Miller ; N.G Cloven; G.F Fleming; A.E Wahner Hendrickson; Azodi, M; DiSilvestro, P; Oza, A; Cristea, M; J.S Berek; J.K Chan; B.J Rimel; Li, Y; Luptakova, K; Clark, R; U.A Matulonis; B.J Monk;
PUBLICAÇÃO: 2018, FONTE: Annals of Oncology, VOLUME: 29

INDEXADO EM:

CrossRef: 4

NO MEU:

ORCID |